Newly published results from the practice-altering REPRIEVE study provide clinicians with greater clarity about the impact of statin use on comorbidity prevention in people with HIV. They also provide an opportunity to more broadly take stock of what statins can and cannot do for patients living with HIV, and for whom statins are most worthy of consideration.
Read the full news story at TheBodyPro.
Source : TheBodyPro
Related HIV and Co-Infections News
-
ESCMID: HIV treatment reduces accelerated biological aging by nearly four years, landmark study shows
-
NDTV: Mpox can infect and replicate in the brain, NIH researchers say in fatal HIV case
-
[CROI 2026] TheBodyPro: Why chronic inflammation drives multimorbidity in people with HIV, despite viral suppression
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.